RxDoctor Payments Data

Thomas Carter, MD

Internal Medicine · la Jolla, CANPI 1912952052

Payments from drug & device makers

$1,348in general payments, 2019–2025

Across 13 payments — averaging $103.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$642
  • Trice Medical, Inc.$200
  • Amgen$121
  • AstraZeneca$116
  • Teva Pharmaceuticals USA, Inc.$112
  • Johnson & Johnson$90
  • plus $67 from 3 others

What the payments were for

  • Speaking & faculty fees$20015%
  • Travel & lodging$30022%
  • Food & beverage$84763%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,348 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$52,899
Medicare patients
236
Services billed
618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$36,162
JardianceEmpagliflozin12$13,266
Atorvastatin Calcium292$3,281
SynthroidLevothyroxine Sodium49$3,133
Levothyroxine Sodium160$2,119
Rosuvastatin Calcium155$2,075
Tamsulosin Hcl73$1,385
GamastanImmune Globul G (Igg)/Glycine13$1,282
Omeprazole66$1,244
Metformin Hcl89$1,167
Losartan Potassium106$1,066
Valsartan31$937
Amlodipine Besylate122$932
Pantoprazole Sodium53$876
Metoprolol Succinate32$868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$34$3,13349 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$112$41730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →